The biologics contract development and manufacturing (CDMO) market is experiencing rapid growth and is dominated by global players with investments in large scale stainless steel capacity.
But is larger always better? Not necessarily says Celonic, a mid-sized, privately owned CDMO, who has been embracing next generation technologies to help small to large biotech customers bring their drugs reliably, effectively and efficiently to the market.
Patient-Centric CDMO Services – Expertise in Bioprocess Tech Transfers
Sponsored PublicationsAs a Contract Development and Manufacturing Organization (CDMO), mAbxience is committed to advancing biologics production and to ensuring that patients receive life-saving treatments faster and with uncompromising quality.
Lab Reagents made with ARTES – recombinant Proteins for lab research
ProductsARTES offers a brand-new business area making the hearts of all R&D staff beat faster. We have a whole range of first-class antigens, enzymes and functional proteins just waiting to be used in new, exciting projects.
Long version of The BIOSECURE Act: The West’s Wake-Up Call to China’s Biotech Dominance
Latest NewsBy Jeremy Levin, D.Phil, MB BChir
The importance of disaccharide excipients in biologics
Sponsored PublicationsDFE Pharma, a world leader in excipients, has expanded into the biopharmaceutical market with its BioHale® portfolio, specifically designed for biologics.
Asabys Partners close €180m Sabadell Asabys II Fund
Latest NewsAsabys Partners have announced the closing of a new oversubscribed fund aimed at investing in 12-15 companies across all areas of pharma biotech.
A “Pure Play” Biologics Swiss-based CDMO
Sponsored PublicationsThe biologics contract development and manufacturing (CDMO) market is experiencing rapid growth and is dominated by global players with investments in large scale stainless steel capacity.
But is larger always better? Not necessarily says Celonic, a mid-sized, privately owned CDMO, who has been embracing next generation technologies to help small to large biotech customers bring their drugs reliably, effectively and efficiently to the market.
The West’s wake-up call to China’s biotech dominance
BackgroundThe U.S. House of Representatives recently passed the BIOSECURE Act, prohibiting U.S. biopharma companies from working with Chinese contractors due to national security concerns, including data leaks and intellectual property theft. The Act is expected to pass the Senate.
White Paper: How Does PAT Apply to the Bioreactor?
Sponsored PublicationsDownload Hamilton’s comprehensive white paper and explore what PAT (Process Analytical Technology) means in Biopharma Upstream processes. Discover cutting-edge sensor solutions to effectively monitor critical process parameters and ensure product quality and reproducibility.
Genespire raises US$52m in Series B round
Latest NewsItalian SR-Tiget spin out Genespire srl will use the proceeds of a €46.6m (US$52m) Series B financing to advance its paediatric in-vivo gene therapy for the rare metabolic disorder Methylmalonic Acidemia (MMA) to Phase I/II testing.
AMR Accelerator urges long-term funding
Latest NewsAntimicrobial resistance (AMR) poses a huge threat to the prevention and treatment of a growing number of infections caused by bacteria, parasites, viruses, and fungi. A public-private partnership involving nine European projects and 98 organisations is now calling for long-term investment to maintain Europe’s ability to research and develop new antibiotics.